The objective of this study is to identify and validate metastasis protein markers in lymph collected from women with metastatic breast cancer. We will examine peripheral blood for the presence of these identified markers in order to develop a user friendly clinical test to detect metastasis and to evaluate response to therapy.
The goal of the study is to identify node-negative breast cancer patients who are unlikely to benefit from adjuvant chemotherapy, thus saving them from the adverse effects of unnecessary treatment. We propose to identify and validate protein markers that can determine breast cancer recurrence and metastasis, based on an approach our group has recently found highly promising for biomarker discovery. The objective of our research is to identify and validate metastasis protein markers in lymph collected from vessels exiting from the primary tumor and prior to their entry into sentinel lymph node in women with metastatic breast cancer. Realizing that this novel procedure cannot be adopted for routine clinical use, we will examine the peripheral blood for the presence of these identified markers in order to develop a user friendly clinical test to detect metastasis and to evaluate response to therapy.
Study Type
OBSERVATIONAL
Enrollment
50
Indiana University Hospital
Indianapolis, Indiana, United States
Identification and Validation of Metastasis Protein Markers
Lymph fluid collected at surgery; blood collected at surgery and then every 6 months for 5 years.
Time frame: Every 6 mo. for 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.